OpenAI Acquires Biotech Startup Orchestra Bio to Expand Healthcare Presence

Artificial intelligence leader OpenAI has taken a major step into the healthcare and biotechnology sectors by acquiring Orchestra Bio, a biotech company led by Ashoka Rajendra. The acquisition aims to expand OpenAI's footprint in healthcare and speed up the process of discovering new medicines using AI technology.

Orchestra Bio, founded in San Francisco, developed a software platform that uses AI agents to streamline biopharma projects from early drug discovery to clinical trials. As part of the acquisition, Orchestra Bio's team and technology will be integrated into OpenAI's 'Rosalind' platform, enabling researchers to better analyze data and accelerate drug development.

Orchestra Bio had previously raised nearly $20 million from investment firms including Andreessen Horowitz and 8VC. Financial details of the deal were not disclosed. The integration is expected to significantly boost the use of artificial intelligence in medical research, with full details of the transaction expected soon.